Former psychiatry division director in the Food and Drug Administration (FDA) Dr. Thomas Laughren has joined pharmaceutical company developing second generation psychedelics for neuro-psychiatric disorders BetterLife Pharma Inc. (CNSX: BETR) (OTCQB : BETRF) as a regulatory advisor.
Previously, Dr. Thomas Laughren served as the Director for the Division of Psychiatry Products, Center for Drug Evaluation and Research at the FDA.
This announcement was made by the company’s Chief Executive Officer Dr. Ahmad Doroudian who said Dr. Laughren brings with him the vast experience he acquired over the years as a psychiatric drug regulator.
“We are thrilled to have Dr. Laughren join the Company as Regulatory Advisor. He brings invaluable psychiatric drug regulatory and development experience for our pipeline as we ramp up our IND-enabling activities,” said the CEO.
